Tzali Cnaani of Carmel Diagnostics speaks to us about improving IVF.
First of all, how are you and your family doing in these COVID-19 times?
Tzali Cnaani: We are OK, now everybody is vaccinated
Tell us about you, your career, how you founded Carmel Diagnostics.
Tzali Cnaani: I joined to run Lumitest, the predecessor of Carmel Diagnostics, which I founded after acquiring the assets of Lumitest from its previous owners and run it since then (02/2009).
Please see my career on LinkedIn.
How does Carmel Diagnostics innovate?
Tzali Cnaani: We developed our system for measuring oxidative stress in body fluids and biological fluids and then focused on our lead application – Embryo selection in the IVF process. Since the system and the technology is a platform, we plan to add more applications. The first one is “early alert for preeclampsia”, and a study started in Rambam medical centre last month. Previously we had successful proof of concept study for risk stratification of Heart Failure patients. Further, the activity requires huge resources.
How the coronavirus pandemic affects your business, and how are you coping?
Tzali Cnaani: The major obstacle is the “closed sky”. We cannot promote the activity that we started in China through CIP – China Israel park and promote investments that we seek in China.
Did you have to make difficult choices, and what are the lessons learned?
Tzali Cnaani: As mentioned, the pandemic did not hurt us except for the “blocking” and the atmosphere it brought to companies and potential investors. At this point, our decision is to go forward with the preeclampsia study and proactively seek investment or partnership.
What specific tools, software and management skills are you using to navigate this crisis?
Tzali Cnaani: Zoom is actually the tool that we frequently use. We keep our contacts, have a presentation at conferences and other opportunities. The idea is to continue with connections we had, develop them and know new partners, which we do through virtual meetings.
Who are your competitors? And how do you plan to stay in the game?
Tzali Cnaani: Our competitors are Vitrolife, Merck Serono with their time-lapse solutions. We plan to compete with our new concept, sensitive device and affordable solution.